72 Investment Holdings’s Entrada Therapeutics TRDA Stock Holding History

72 Investment Holdings’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-172,600	Closed	-$2.6M	–	8
2023 Q4	$2.6M	Sell	172,600 -336,423	-66%	-$4.98M	11.57%	3
2023 Q3	$8.04M	Hold	509,023	–	–	53.88%	1
2023 Q2	$7.71M	Hold	509,023	–	–	60.04%	1
2023 Q1	$7.38M	Hold	509,023	–	–	3.5%	2
2022 Q4	$6.88M	Hold	509,023	–	–	3.16%	2
2022 Q3	$8.02M	Hold	509,023	–	–	6.35%	2
2022 Q2	$6.2M	Hold	509,023	–	–	9.58%	2
2022 Q1	$4.78M	Sell	509,023 -1	-0%	-$11	5.23%	3
2021 Q4	$8.71M	Buy	+509,024	New	+$12.3M	7.73%	3

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

72 Investment Holdings's TRDA Position: Q1 2024 in Review

72 Investment Holdings sold out of Entrada Therapeutics (TRDA) in Q1 2024, closing a stake of 172,600 shares — an estimated $2.6M sold.

72 Investment Holdings first reported a position in TRDA in Q4 2021 and held it in 9 quarters. The position peaked at $8.71M in Q4 2021. 77 funds tracked by Wall St. Rank hold TRDA as of Q1 2024.

72 Investment Holdings reported no remaining Entrada Therapeutics position as of Q1 2024 after selling out during the quarter.
72 Investment Holdings sold 172,600 Entrada Therapeutics shares in Q1 2024, an estimated $2.6M.
72 Investment Holdings first reported a position in Entrada Therapeutics in Q4 2021 and held it in 9 quarters.
72 Investment Holdings's Entrada Therapeutics position peaked at $8.71M in Q4 2021.
77 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2024.

Based on 72 Investment Holdings's 13F filing for Q1 2024, filed 15 May 2024.